2nd progressive vision loss drug by Biogen fails in late-stage trial

Another gene therapy for progressive vision loss developed by Biogen Inc. (Nasdaq: BIIB) has failed in a late-stage clinical trial, the company announced Monday. The drug, designed to target the rare genetic blindness disorder choroideremia, did not show significant benefit 12 months after treatment in a Phase 3 study involving 169 men with the disease. Biogen says it will evaluate the complete dataset before deciding on next steps for the drug's developme nt. This is the second failure in as many…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news